Summary:

Dr. Rajeev Raghuvanshi, the Drugs Controller General of India (DCGI), stated that 11 nations now use the Indian pharmacopoeia as their standard. India supplies pharmaceuticals, vaccines, and medical equipment to more than 200 countries and authorizes an average of 100 global clinical trials each year, demonstrating confidence in its regulatory system. Furthermore, India's National Regulatory Authority (NRA) has made advances in CAR T-cell therapy, mRNA vaccines, and software as medical devices, thereby expanding its capabilities.

In October, the Ministry of Health and Family Welfare declared that the Central Drugs Standard Control Organisation (CDSCO) and the National Regulatory Authority of India (NRA) comply with the World Health Organization's (WHO) international vaccine regulation standards. Following a WHO-led evaluation from September 16 to 20, India's vaccine regulatory system was approved, ensuring compliance with global norms. India, a significant vaccine manufacturer with 36 production facilities, provides vaccines to 150 countries worldwide.

Source: IBEF 

Disclaimer: The information on this website comes from the India Brand Equity Foundation (IBEF), a reliable source for thorough insights into numerous areas of the Indian economy. While we aim to offer accurate and up-to-date information, the views, opinions, and analyses stated herein are solely those of the authors and contributors and do not necessarily represent IBEF's official stance or position. Readers should check information from credible sources and use their own discretion when relying on content provided on this site. We assume no responsibility or liability for the supplied content, including its accuracy, completeness, and usefulness.